Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 14, No. 3, 2015, pp. 391-397
Bioline Code: pr15052
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 14, No. 3, 2015, pp. 391-397
© Copyright 2015 - Tropical Journal of Pharmaceutical Research
siRNAs Targeting Viral Protein 5: The Major Capsid Protein of Herpes Simplex Virus-1 Affects its Propagation and Cytoskeleton|
Ma, Kaiqi; Jin, Fujun; Wang, Qiaoli; Ren, Zhe; Zheng, Kai & Wang, Yifei
Purpose: To investigate whether siRNA targeting viral protein 5 (VP5) can become a new treatment for
herpes simplex virus type 1 (HSV-1).
Methods: Flow cytometry was performed to determine the ratio of siRNA and lipo2000 to reach the
highest transfection efficiency. Western blot and q-PCR were performed to determine the knockdown
efficiency of siRNA targeting UL19, as well as changes in cytoskeleton proteins. Plaque reduction
assays and confocal microscopy were conducted to test the influence of VP5 knockdown on the HSV-1
life cycle and viral replication. F-actin organization was observed through confocal microscopy during
HSV-1 infection when transfected with siRNA.
Results: Relative expression level of the UL19 gene dropped to 6 % while plaque formation inhibition
rate rose to 85 % compared with virus control. Knocking down VP5 expression abrogated the changes
to F-actin that were induced by HSV-1 infection.
Conclusion: Interfering with UL19 gene expression inhibits HSV-1 replication efficiently in vitro. The
results indicate that the major capsid protein VP5 encoding gene UL19 may be a promising target for
RNA interference-based therapeutic strategy against HSV-1.
siRNA; Viral protein 5; Herpes simplex virus type 1; Gene expression; Propagation; Cytoskeleton rearrangement; F-actin; Transfection
Alternative site location: http://www.tjpr.org